New hope for psoriasis patients who Didn't respond to leading therapies
NCT ID NCT06336343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called bimekizumab in 60 adults with moderate-to-severe plaque psoriasis who had not improved with other similar treatments. The drug works by blocking certain inflammatory substances in the body to reduce skin redness, scaling, and thickness. The main goal was to see if it could clear most of the psoriasis, with less than 1% of the body affected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, 08520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a new drug called ZP9830 calm psoriasis Flare-Ups?
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- New oral pill TLL018 aims to clear psoriasis plaques in phase 2 trial